The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Nov

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

David A. Hyman, MD, JD, on Inclusive Shared Savings

Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies

One Surgery Could Prevent Most Ovarian Cancers

ASTRO Experts Comment on the Results of the SUPREMO Trial

SLNB Alone vs Lymphadenectomy in Cervical Cancer

Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC